🏛️ Verified NIH Record • Updated 2025-03-19
NOVOCART 3D Treatment Following Microfracture Failure (NCT03219307)
Safety and Efficacy of NOVOCART 3D in the Treatment of Articular Cartilage Defects Following Failure on Microfracture
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Aesculap Biologics, LLC
🩺 Plain-English Summary (8th-Grade Level)
This study is prospective single arm extension study of protocol AAG-G-H-1220. It is open only to participants of AAG-G-H-1220 randomized to the Microfracture treatment group.
Who can join: Review the eligibility criteria below.
Location: Rush University Medical Center — Chicago, Illinois
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Rush University Medical Center — Chicago, Illinois
- Ohio State University Wexner Medical Center — Columbus, Ohio
- Alpine Orthopaedics — North Logan, Utah
- University of Alberta — Edmonton, Alberta
- Dalhousie University — Halifax, Nova Scotia
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Articular Cartilage Defect
- Phase 2 Clinical Trial of CartiLife® in the United States — Irvine, California
Explore by condition: All Articular Cartilage Defect clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.